메뉴 건너뛰기




Volumn 50, Issue 11, 2010, Pages 1330-1338

Does the long plasma half-life of 4β-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?

Author keywords

4 hydroxycholesterol; CYP3A; Cytochrome P450 3A; induction; inhibition; simulation

Indexed keywords

4BETA HYDROXYCHOLESTEROL; ATAZANAVIR PLUS RITONAVIR; CARBAMAZEPINE; CHOLESTEROL DERIVATIVE; CYTOCHROME P450 3A; KETOCONAZOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; RITONAVIR; UNCLASSIFIED DRUG;

EID: 78449302623     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009360041     Document Type: Review
Times cited : (31)

References (43)
  • 1
    • 0032924934 scopus 로고    scopus 로고
    • Cytochrome P-450 3A4: Regulation and role in drug metabolism
    • Guengerich FP Cytochrome P-450 3A4: regulation and role in drug metabolism, Annu Rev Pharmacol Toxicol. 1999 ; 39: 1-17.
    • (1999) Annu Rev Pharmacol Toxicol , vol.39 , pp. 1-17
    • Guengerich, F.P.1
  • 2
    • 0033972441 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
    • Dresser GK, Spence JD, Bailey DG Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 ; 38: 41-57.
    • (2000) Clin Pharmacokinet , vol.38 , pp. 41-57
    • Dresser, G.K.1    Spence, J.D.2    Bailey, D.G.3
  • 3
    • 0030009690 scopus 로고    scopus 로고
    • Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo
    • von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol. 1996 ; 16: 104-112.
    • (1996) J Clin Psychopharmacol , vol.16 , pp. 104-112
    • Von Moltke, L.L.1    Greenblatt, D.J.2    Duan, S.X.3    Harmatz, J.S.4    Wright, C.E.5    Shader, R.I.6
  • 5
    • 0033977595 scopus 로고    scopus 로고
    • Metabolic interactions between mibefradil and HMGCoA reductase inhibitors: Linking in vitro with in vivo information
    • Mück W. Metabolic interactions between mibefradil and HMGCoA reductase inhibitors: linking in vitro with in vivo information. Br J Clin Pharmacol. 2000 ; 49: 87-90.
    • (2000) Br J Clin Pharmacol , vol.49 , pp. 87-90
    • Mück, W.1
  • 6
    • 0032700543 scopus 로고    scopus 로고
    • Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
    • Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999 ; 66: 461-471.
    • (1999) Clin Pharmacol Ther , vol.66 , pp. 461-471
    • Tsunoda, S.M.1    Velez, R.L.2    Von Moltke, L.L.3    Greenblatt, D.J.4
  • 8
    • 0033309227 scopus 로고    scopus 로고
    • Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity
    • McCrea J., Prueksaritanont T., Gertz BJ, et al. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol. 1999 ; 39: 1212-1220.
    • (1999) J Clin Pharmacol , vol.39 , pp. 1212-1220
    • McCrea, J.1    Prueksaritanont, T.2    Gertz, B.J.3
  • 9
    • 1642494659 scopus 로고    scopus 로고
    • Cocktail" approaches and strategies in drug development: Valuable tool or flawed science
    • Zhou H., Tong Z., McLeod JF " Cocktail" approaches and strategies in drug development: valuable tool or flawed science ? J Clin Pharmacol. 2004 ; 44: 120-134.
    • (2004) J Clin Pharmacol , vol.44 , pp. 120-134
    • Zhou, H.1    Tong, Z.2    McLeod, J.F.3
  • 10
    • 0031868142 scopus 로고    scopus 로고
    • Urinary excretion of 6β-hydroxycortisol as an in vivo marker for CYP3A induction: Applications and recommendations
    • Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK Urinary excretion of 6β-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther. 1999 ; 63: 617-622.
    • (1999) Clin Pharmacol Ther , vol.63 , pp. 617-622
    • Kovacs, S.J.1    Martin, D.E.2    Everitt, D.E.3    Patterson, S.D.4    Jorkasky, D.K.5
  • 11
    • 0037200017 scopus 로고    scopus 로고
    • Metabolism of 4β-hydroxycholesterol in humans
    • Bodin K., Andersson U., Rystedt E., et al. Metabolism of 4β-hydroxycholesterol in humans. J Biol Chem. 2002 ; 277: 31534-31540.
    • (2002) J Biol Chem , vol.277 , pp. 31534-31540
    • Bodin, K.1    Andersson, U.2    Rystedt, E.3
  • 12
    • 0035914368 scopus 로고    scopus 로고
    • Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans: Evidence for involvement of cytochrome P450 3A4
    • Bodin K., Bretillon L., Aden Y., et al. Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans: evidence for involvement of cytochrome P450 3A4. J Biol Chem. 2001 ; 276: 38685-38689.
    • (2001) J Biol Chem , vol.276 , pp. 38685-38689
    • Bodin, K.1    Bretillon, L.2    Aden, Y.3
  • 13
    • 64749098311 scopus 로고    scopus 로고
    • Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS
    • Honda A., Yamashita K., Hara T., et al. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J Lipid Res. 2009 ; 50: 350-357.
    • (2009) J Lipid Res , vol.50 , pp. 350-357
    • Honda, A.1    Yamashita, K.2    Hara, T.3
  • 14
    • 42149130238 scopus 로고    scopus 로고
    • Time course of the increase in 4β-hydroxycholesterol concentration during carbamazepine treatment of pediatric patients with epilepsy
    • Wide K., Larsson H., Bertilsson L., Diczfalusy U. Time course of the increase in 4β-hydroxycholesterol concentration during carbamazepine treatment of pediatric patients with epilepsy. Br J Clin Pharmacol. 2008 ; 65: 708-715.
    • (2008) Br J Clin Pharmacol , vol.65 , pp. 708-715
    • Wide, K.1    Larsson, H.2    Bertilsson, L.3    Diczfalusy, U.4
  • 15
    • 54249101311 scopus 로고    scopus 로고
    • Cytochrome P450 induction by rifampicin in healthy subjects: Determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4β-hydroxycholesterol
    • Kanebratt K., Diczfalusy U., BàCurrency signckström T. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4β- hydroxycholesterol. Clin Pharmacol Ther. 2008 ; 84: 589-594.
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 589-594
    • Kanebratt, K.1    Diczfalusy, U.2    BàCurrencysignckström, T.3
  • 16
    • 58149129621 scopus 로고    scopus 로고
    • 4β-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity: Stability and half-life of elimination after induction with rifampicin
    • Diczfalusy U., Kanebratt KP, Bredberg E., Andersson TB, Böttiger Y., Bertilsson L. 4β-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity: stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol. 2009 ; 67: 38-43.
    • (2009) Br J Clin Pharmacol , vol.67 , pp. 38-43
    • Diczfalusy, U.1    Kanebratt, K.P.2    Bredberg, E.3    Andersson, T.B.4    Böttiger, Y.5    Bertilsson, L.6
  • 18
    • 45849151673 scopus 로고    scopus 로고
    • CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels
    • Josephson F., Bertilsson L., Böttiger Y., et al. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels. Eur J Clin Pharmacol. 2008 ; 64: 775-781.
    • (2008) Eur J Clin Pharmacol , vol.64 , pp. 775-781
    • Josephson, F.1    Bertilsson, L.2    Böttiger, Y.3
  • 19
    • 40049103597 scopus 로고    scopus 로고
    • 4β-hydroxycholesterol is a new endogenous CYP3A marker: Relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
    • Diczfalusy U., Miura J., Roh HK,, et al. 4β-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics. 2008 ; 18: 201-208.
    • (2008) Pharmacogenet Genomics , vol.18 , pp. 201-208
    • Diczfalusy, U.1    Miura, J.2    Roh, H.K.3
  • 20
    • 10744232330 scopus 로고    scopus 로고
    • The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    • Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER)
    • Bjornsson TD, Callaghan JT, Einolf HJ,, et al. Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003 ; 31: 815-832.
    • (2003) Drug Metab Dispos , vol.31 , pp. 815-832
    • Bjornsson, T.D.1    Callaghan, J.T.2    Einolf, H.J.3
  • 21
    • 40049084668 scopus 로고    scopus 로고
    • Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: Proposed refinement and expansion of the "rank order" approach
    • Rodrigues AD Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach. Drug Metab Lett. 2007 ; 1: 31-35.
    • (2007) Drug Metab Lett , vol.1 , pp. 31-35
    • Rodrigues, A.D.1
  • 22
    • 0033770918 scopus 로고    scopus 로고
    • Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation
    • Palovaara S., Kivistö KT, Tapanainen P., Manninen P., Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′- hydroxylation. Br J Clin Pharmacol. 2000 ; 50: 333-337.
    • (2000) Br J Clin Pharmacol , vol.50 , pp. 333-337
    • Palovaara, S.1    Kivistö, K.T.2    Tapanainen, P.3    Manninen, P.4    Neuvonen, P.J.5    Laine, K.6
  • 23
    • 0029987745 scopus 로고    scopus 로고
    • Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam
    • Zimmermann T., Yeates RA, Laufen H., Scharpf F., Leitold M., Wildfeuer A. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung. 1996 ; 46: 213-217.
    • (1996) Arzneimittelforschung , vol.46 , pp. 213-217
    • Zimmermann, T.1    Yeates, R.A.2    Laufen, H.3    Scharpf, F.4    Leitold, M.5    Wildfeuer, A.6
  • 26
    • 0021647847 scopus 로고
    • The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam
    • Elliott P., Dundee JW, Elwood RJ, Collier PS The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam. Eur J Anaesthesiol. 1984 ; 1: 245-251.
    • (1984) Eur J Anaesthesiol , vol.1 , pp. 245-251
    • Elliott, P.1    Dundee, J.W.2    Elwood, R.J.3    Collier, P.S.4
  • 27
    • 0142040171 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone
    • Lam YW, Alfaro CL, Ereshefsky L., Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol. 2003 ; 43: 1274-1282.
    • (2003) J Clin Pharmacol , vol.43 , pp. 1274-1282
    • Lam, Y.W.1    Alfaro, C.L.2    Ereshefsky, L.3    Miller, M.4
  • 28
    • 0031028102 scopus 로고    scopus 로고
    • Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam
    • Ahonen J., Olkkola KT, Neuvonen PJ Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol. 1997 ; 51: 415-419.
    • (1997) Eur J Clin Pharmacol , vol.51 , pp. 415-419
    • Ahonen, J.1    Olkkola, K.T.2    Neuvonen, P.J.3
  • 30
    • 0027477751 scopus 로고
    • A potentially hazardous interaction between erythromycin and midazolam
    • Olkkola KT, Aranko K., Luurila H., et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993 ; 53: 298-305.
    • (1993) Clin Pharmacol Ther , vol.53 , pp. 298-305
    • Olkkola, K.T.1    Aranko, K.2    Luurila, H.3
  • 32
    • 0029664974 scopus 로고    scopus 로고
    • The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
    • Olkkola KT, Ahonen J., Neuvonen PJ The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996 ; 82: 511-516.
    • (1996) Anesth Analg , vol.82 , pp. 511-516
    • Olkkola, K.T.1    Ahonen, J.2    Neuvonen, P.J.3
  • 33
    • 33645847236 scopus 로고    scopus 로고
    • Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
    • Saari TI, Laine K., Leino K., Valtonen M., Neuvonen PJ, Olkkola KT Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther. 2006 ; 79: 362-370.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 362-370
    • Saari, T.I.1    Laine, K.2    Leino, K.3    Valtonen, M.4    Neuvonen, P.J.5    Olkkola, K.T.6
  • 34
    • 7944237810 scopus 로고    scopus 로고
    • Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis
    • Kharasch ED, Walker A., Hoffer C., Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther. 2004 ; 76: 452-466.
    • (2004) Clin Pharmacol Ther , vol.76 , pp. 452-466
    • Kharasch, E.D.1    Walker, A.2    Hoffer, C.3    Sheffels, P.4
  • 35
    • 36148968010 scopus 로고    scopus 로고
    • Drug interaction studies of therapeutic proteins or monoclonal antibodies
    • Mahmood I., Green MD Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol. 2007 ; 47: 1540-1554.
    • (2007) J Clin Pharmacol , vol.47 , pp. 1540-1554
    • Mahmood, I.1    Green, M.D.2
  • 36
    • 41149106199 scopus 로고    scopus 로고
    • Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: Reality check
    • Seitz K., Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007 ; 47: 1104-1118.
    • (2007) J Clin Pharmacol , vol.47 , pp. 1104-1118
    • Seitz, K.1    Zhou, H.2
  • 37
    • 0027530759 scopus 로고
    • Human cholesterol synthesis measurement using deuterated water: Theoretical and procedure considerations
    • Jones PJ, Leitch CA, Li ZC, Connor WE Human cholesterol synthesis measurement using deuterated water: theoretical and procedure considerations. Arterioscler Thromb Vasc Biol. 1993 ; 13: 247-253.
    • (1993) Arterioscler Thromb Vasc Biol , vol.13 , pp. 247-253
    • Jones, P.J.1    Leitch, C.A.2    Li, Z.C.3    Connor, W.E.4
  • 38
    • 33645106219 scopus 로고    scopus 로고
    • Cholesterol-metabolizing cytochromes P450
    • Pikuleva IA Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 ; 34: 513-520.
    • (2006) Drug Metab Dispos , vol.34 , pp. 513-520
    • Pikuleva, I.A.1
  • 39
    • 45549087867 scopus 로고    scopus 로고
    • Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin
    • Magnusson MO, Dahl ML, Cederberg J., Karlsson MO, Sandström R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008 ; 84: 52-62.
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 52-62
    • Magnusson, M.O.1    Dahl, M.L.2    Cederberg, J.3    Karlsson, M.O.4    Sandström, R.5
  • 40
    • 47949115175 scopus 로고    scopus 로고
    • A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro
    • Fahmi OA, Maurer TS, Kish M., Cardenas E., Boldt S., Nettleton D. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos. 2008 ; 36: 1698-1708.
    • (2008) Drug Metab Dispos , vol.36 , pp. 1698-1708
    • Fahmi, O.A.1    Maurer, T.S.2    Kish, M.3    Cardenas, E.4    Boldt, S.5    Nettleton, D.6
  • 41
    • 54349113314 scopus 로고    scopus 로고
    • Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction
    • Shou M., et al. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos. 2008 ; 36: 2355-2370.
    • (2008) Drug Metab Dispos , vol.36 , pp. 2355-2370
    • Shou, M.1
  • 42
    • 27444445468 scopus 로고    scopus 로고
    • Prediction of in vivo drug-drug interactions from in vitro data: Impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant
    • Brown HS, Ito K., Galetin A., Houston JB Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol. 2005 ; 60: 508-518.
    • (2005) Br J Clin Pharmacol , vol.60 , pp. 508-518
    • Brown, H.S.1    Ito, K.2    Galetin, A.3    Houston, J.B.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.